Shares of Haleon plc (LON:HLN - Get Free Report) traded down 1.9% on Monday . The stock traded as low as GBX 382.60 ($4.95) and last traded at GBX 385.50 ($4.99). 14,722,720 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 28,321,533 shares. The stock had previously closed at GBX 393.15 ($5.09).
Analysts Set New Price Targets
Separately, Berenberg Bank lifted their price objective on Haleon from GBX 456 ($5.90) to GBX 457 ($5.92) and gave the stock a "buy" rating in a research note on Friday, February 28th.
Check Out Our Latest Stock Analysis on Haleon
Haleon Price Performance
The firm has a market cap of £35.24 billion, a P/E ratio of 32.83, a P/E/G ratio of 1.49 and a beta of 0.19. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The business's 50 day moving average is GBX 386.58 and its two-hundred day moving average is GBX 381.74.
Haleon (LON:HLN - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, analysts anticipate that Haleon plc will post 19.5033282 earnings per share for the current year.
Haleon Increases Dividend
The business also recently announced a dividend, which will be paid on Thursday, June 5th. Investors of record on Thursday, April 24th will be given a dividend of GBX 4.60 ($0.06) per share. This represents a dividend yield of 1.18%. The ex-dividend date is Thursday, April 24th. This is an increase from Haleon's previous dividend of $2.00. Haleon's payout ratio is presently 50.46%.
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.
Further Reading
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
